Le Lézard
Classified in: Health
Subject: FDA

Media Invitation - La Jolla, CA Medical Center, Achieve TMS, Unveils State-of-the-Art/FDA-Approved Neuro-Navigation System

SAN DIEGO, Aug. 5, 2019 /PRNewswire-PRWeb/ -- Achieve TMS, the nation's most trusted deep Transcranial Magnetic Stimulation (dTMS) provider, will begin offering treatments at its La Jolla center using a state-of-the-art and FDA-approved Neuro-Navigation system for patients with depression, OCD and other conditions.

This is the first such system available in San Diego. Achieve TMS will hold a demonstration event for interested media at 5:30 pm on Thursday August 8, 2019 at Achieve TMS La Jolla, located at 4510 Executive Drive, Suite 111, San Diego, 92121. Space is limited and advance notice is required via lsegall(at)achievetms.com.

The informative event will include an introduction and medical explanation of MRI-guided brain mapping neuro-navigation transcranial magnetic stimulation (TMS) system for treating major depressive disorder (MDD) and other treatment-resistant neuropsychiatric conditions. Achieve TMS La Jolla and Drs. Lindsay Oberman, Manish Sheth and Shashita Inamdar will lead the discussion.

MRI-guided neuro-navigation has been successfully used for over 20 years in complex neurosurgical procedures. Now, for the first time, this technology is available via Smart Focus TMS by Nexstim to provide ultra high precision TMS treatment of complex and treatment-resistant neuropsychiatric conditions such as depression, OCD, TBIs, Autism, Addictions and ADHD. This treatment option is now available at Achieve TMS La Jolla.



These press releases may also interest you

at 09:38
MagicMed Industries Inc. ("MagicMed" or "the Company") today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering composition of matter, drug formulation and process of...

at 09:37
The Lawrence J. Ellison Institute for Transformative Medicine of USC ("Ellison Institute") and Oracle reveal a promising two-step technique to train a high-confidence predictive algorithm for enhanced cancer diagnostics. The study uses novel tissue...

at 09:35
Trueblue is making the digital working model of pharmaceutical and life sciences companies more accessible. Trueblue announces the integration of its Artificial Intelligence Relationship Management (AiRM) with Microsoft Dynamics 365 and Power...

at 09:35
A new clinical trial conducted by the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG) is the first in the world to test an immune-stimulating treatment to reduce symptoms and prevent severe cases of COVID-19 and other serious...

at 09:35
ACIST Medical Systems, Inc., a Bracco Group Company, today announced the global launch of its ACIST Navvus II Rapid Exchange FFR MicroCatheter, the second-generation microcatheter for use with its ACIST RXi® Rapid Exchange FFR System. Fractional...

at 09:34
Every six hours, a person dies from a drug overdose in New York City, with more deaths in the Bronx than any other borough. COVID-19 has made the overdose epidemic even more dangerous because many people feel isolated and uncomfortable going to...

News published on 5 august 2019 at 12:00 and distributed by: